Silk Road Medical grows sales 27% in Q1 results

Silk Road Medical (NSDQ:SILK) this week posted first-quarter results that beat the revenue consensus on Wall Street and missed on earnings.

The Sunnyvale, California-based stroke treatment tech company reported losses of $16.7 million, or -48¢ per share, on sales of $28.02 million for the three months ended March 31 for sales growth of 27% compared with Q1 2021.

Earnings per share were 11¢ behind The Street, where analysts were looking for sales of $28.02 million.

“We demonstrated strong execution in the first quarter and remain confident in our ability to drive further TCAR adoption, supplemented by our recent FDA approved label expansion for our stent to include standard surgical risk patients,” CEO Erica Rogers said in a news release. “This approval levels a playing field once dominated by open surgery, allowing an expanded patient population to benefit from our less invasive approach as we establish TCAR as the new standard of care in stroke preventi…

Read more
  • 0

Silk Road Medical grows sales 33% in Q4

Silk Road Medical (NSDQ:SILK) this week posted fourth-quarter results that beat the revenue consensus on Wall Street and missed on earnings estimates.

The Sunnyvale, California-based stroke treatment company reported losses of -$14.7 million, or -42¢ per share, on sales of $28.3 million for the three months ended Dec. 31, 2021, for a bottom-line gain of 12.3% on sales growth of 33.75% compared with Q4 2020.

Earnings per share were 42¢, 7¢ behind The Street, where analysts were looking for sales of $25.91 million.

“Our team and physicians had a tremendous impact in 2021, performing nearly 14,000 cases and driving record annual revenue of $101.5 million,” president and CEO Erica Rogers said in a news release. “We drove measurable progress on regulatory and clinical fronts in anticipation of standard surgical risk approval in the U.S., entry into Japan and China, and development of our long-term pipeline, and we are well-positioned to continue establishing …

Read more
  • 0